Search clinical trials for: beta alethine

Total 6039 results

Indiana University
Office of Naval Research (ONR)

Completed

Mirabegron and Physiological Function in Cold Environments

Resting Energy Expenditure | Brown Adipose Tissue | Thermogenesis

United States
University of Manitoba
Canadian Institutes of Health Research (CIHR); Agriculture and Agri-Food Canada

Completed

Canola Oil, Fibre and DHA Enhanced Clinical Trial

Metabolic Syndrome

Canada
Korea University Anam Hospital

Active, not recruiting

Effect of Different Antihypertensive Drugs on Central Blood Pressure

Hypertension

Korea, Republic of
Astellas Pharma China, Inc.

Completed

A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants

Pharmacokinetics of Mirabegron | Food Effect | Healthy Chinese Subjects

China
Swiss Group for Clinical Cancer Research

Completed

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

Switzerland
CHU de Quebec-Universite Laval

Completed

Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder (Mirabegron)

Overactive Bladder | Urinary Incontinence
Mercy Research
Forest Laboratories

Completed

Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function

Hypertension

United States
Astellas Pharma Inc

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder

Urinary Bladder, Overactive

Japan
AOP Orphan Pharmaceuticals AG

Completed

A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol

Healthy Volunteers | Pharmacokinetics/Dynamics Study

Czech Republic
Mylan Bertek Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

Hypertension

United States
Taipei Veterans General Hospital, Taiwan

Recruiting

Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

Overactive Bladder Syndrome

Taiwan
Purdue University

Completed

Comparing the Gastric Transit of Commercial Milk and A2 Milk

Lactose Intolerance, Adult Type

United States
Southern Illinois University
Astellas Scientific & Medical Affairs, Inc.; Sisters of the Third Order of...

Terminated

Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

Pain | Urinary Bladder, Overactive | Lower Urinary Tract Symptoms

United States
University of Florida
National Institute of General Medical Sciences (NIGMS)

Terminated

Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure

Pulmonary Hypertension | Heart Failure With Preserved Ejection Fraction | Diastolic Heart Failure

United States
Benha University

Completed

Dose Esmolol Infusion Have an Adjuvant Effect to TAP Block for Pain Control in Laparoscopic Cholecystectomy.

Postoperative Pain

Egypt
The University of Texas Health Science Center at...

Completed

Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron (SCIMYR)

Cognitive Change | Spinal Cord Injuries | Neurogenic Bladder

United States
Loyola University
Astellas Pharma US, Inc.

Completed

Mirabegron and Urinary Urgency Incontinence

Overactive Bladder

United States
Buddhist Tzu Chi General Hospital

Unknown

Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Overactive Bladder Syndrome

Taiwan
Biocad

Completed

Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers

Healthy

Russian Federation
Astellas Pharma Inc

Completed

A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients

Urinary Bladder, Overactive

Japan
Astellas Pharma Inc

Completed

Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

Overactive Bladder | Cardiovascular Disease

Japan
Astellas Pharma Inc

Completed

Drug Use-Results Survey of Betanis Tablets in Japan

Overactive Bladder

Japan
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene Corporation

Completed

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Myelodysplastic Syndromes

France
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease (REAL)

Alzheimer's Disease

Italy
Astellas Pharma Inc

Completed

A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects

Intraocular Pressure

United States
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Healthy Subjects | Pharmacokinetics | Mild and Moderate Hepatic Impairment

Slovakia
GlaxoSmithKline

Completed

A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

Irritable Bowel Syndrome (IBS)

United States
Mylan Bertek Pharmaceuticals

Completed

A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients

Hypertension

United States
National Cancer Institute (NCI)

Active, not recruiting

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Biogen
Elan Pharmaceuticals

Terminated

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)

Relapsing Remitting Multiple Sclerosis

United States, Czech Republic, Italy, Spain, Sweden, Latvia, Finland, Hungary, Poland, Slovenia, Australia, Canada, France
Biogen

Completed

Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis (SIMCOMBIN)

Multiple Sclerosis

Denmark
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
Uma Borate

Suspended

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Fred Hutchinson Cancer Center
Pfizer

Completed

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Acute Myeloid Leukemia

United States
University of Belgrade

Completed

Effect of Alveolar Ridge Preservation on Implant Esthetic Outcomes

Partial Edentulism

Serbia
First Affiliated Hospital of Zhejiang University

Recruiting

Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients

Severe Sepsis

China
Assiut University

Not yet recruiting

Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Risk of COVID_19

COVID-19 Pneumonia
Assistance Publique - Hôpitaux de Paris
Groupe Hospitalier Pitie-Salpetriere

Completed

Beta Blocker Interruption After Uncomplicated Myocardial Infarction (AβYSS)

Myocardial Infarction

France
Johns Hopkins University
Astellas Pharma US, Inc.

Completed

Mirabegron For Erectile Dysfunction

Overactive Bladder | Urinary Incontinence | Erectile Dysfunction

United States
State University of New York at Buffalo
Astellas Pharma Inc

Withdrawn

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

Urinary Frequency/Urgency | Bladder Pain Syndrome | Bladder Irritable

United States
Hospital de Base

Unknown

The Effects of Esmolol on the Hemodynamic Response to Orotracheal Extubation

Hemodynamic Instability | Beta Blocker

Brazil
Mansoura University

Unknown

Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study

Prostatic Neoplasms | Erectile Dysfunction | BPH | Prostate Hyperplasia | Erectile Abnormalities

Egypt
M.D. Anderson Cancer Center

Completed

Mesenchymal Stem Cells (MSC) for Ovarian Cancer

Ovarian Cancer

United States
Fundación Centro Nacional de Investigaciones Cardiovasculares...
Hospital Clinic of Barcelona; Fundació Institut de Recerca de l'Hospital de... and other collaborators

Unknown

Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure (SPHERE-HF)

Heart Failure | Pulmonary Hypertension | Mirabegron | Pulmonary Vascular Resistance Abnormality
Karolinska Institutet

Completed

Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists

Overactive Bladder

Sweden
Rempex Pharmaceuticals (a wholly owned subsidiary...

Completed

Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination

Bacterial Infections | Healthy Volunteers

Australia
Astellas Pharma Inc

Completed

A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex

Healthy Volunteers | Pharmacokinetics of Mirabegron

France
Astellas Pharma China, Inc.

Completed

Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers

Healthy Chinese Volunteers

China
Biogen

Completed

A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects

Healthy

China
Weill Medical College of Cornell University
U.S. Deprescribing Research Network

Recruiting

N-of-1 for Beta-Blockers in Cardiac Amyloidosis

Heart Diseases | Cardiac Amyloidosis

United States

Search clinical trials for: beta alethine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations